Great news for Part D beneficiaries as it nears its 10 year anniversary

08.01.13 | By

As we approach the 10 year anniversary of Part D being signed into law, more good news recently came out of CMS about the program. Their data showed that average monthly premiums are projected to stay stable at $31 for the 2014 plan year. Additionally, the Part D deductible will decrease from $325 to $310 next year – creating more savings for beneficiaries.

New Survey Identifies America’s Health Priorities: Obesity, Cancer Cures, Senior Care

WASHINGTON, D.C. (August 2, 2013) – A new survey commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities, followed by developing effective treatments for heart disease (78 percent) and more intensive medical care for seniors (76 percent).

PhRMA's First Annual Survey

08.01.13 | By

How long do you think you’ll live? Do you feel like you had a pretty good health year thus far? What about your neighbors and those in your community – how’s their year been, health-wise? What cures do you think will be discovered next in medicine?

The Need to Address Diseases and Disorders of the Brain

07.31.13 | By

The human brain, despite weighing just 3 pounds, contains over 100 billion neurons -- to say that it's complex is an understatement. These neurons are responsible for receiving messages and forwarding them to the appropriate parts of the brain, which in turn control everything we do. Considering the millions of tiny actions that make up just one day of your life, we may underappreciate just how much the brain can do for a person until something happens to it.

Understanding the benefit-risk balance of medicines

07.30.13 | By

The assessment of benefits and risks is critical in the development of new medicines. Last year’s reauthorization of the Prescription Drug User Fee Act (PDUFA) included a new Patient-Focused Drug Development initiative at the Food and Drug Administration (FDA) to gain patient insight, including perspectives on the benefit-risk balance of medicines, in 20 disease states over five years.

Conversations Round-Up

07.30.13 | By

Every person is unique, and so are the challenges they face when it comes to their health. However, there are some core opportunities to improve care across wide swaths of the population, and that’s why we asked last week’s Conversations question: “What are the biggest challenges and opportunities when it comes to improving patient health?”

Answering the Call

07.25.13 | By

On Monday, the Personalized Medicine Coalition convened leaders from the field on Capitol Hill to discuss the promise of personalized medicine and the implications for policy-makers. A number of important issues were raised (more on that in my next post), but the highlight was remarks by Stephanie Haney. Stephanie is a lung cancer patient and mother of two who said she is alive today thanks to a novel personalized medicine.

Responsibly Sharing Clinical Research Results Will Enhance Scientific Knowledge and Advance Patient Care

07.24.13 | By

The biopharmaceutical industry is firmly committed to enhancing public health through responsible reporting and publication of clinical research and safety information.

New Trade Free Agreement

07.24.13 | By

Today, PhRMA President and CEO John Castellani testified before the House Energy and Commerce subcommittee on Commerce, Manufacturing and Trade about an ambitious new free trade agreement being negotiated between the United States and the European Union.

In Malaysia, Protecting IP Fosters Economic Growth

07.23.13 | By

This week, negotiators conclude the 18th round of Trans-Pacific Partnership (TPP) negotiations in Malaysia. The agreement, which includes Malaysia and 11 other nations, not only provides the United States with an entrée into the Asia Pacific region, but also opens new markets for all participating countries. But for this agreement to be beneficial globally, it must include strong intellectual property protections.


Subscribe to RSS - Opinion